308 related articles for article (PubMed ID: 23122780)
1. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
2. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Bellera CA; Penel N; Ouali M; Bonvalot S; Casali PG; Nielsen OS; Delannes M; Litière S; Bonnetain F; Dabakuyo TS; Benjamin RS; Blay JY; Bui BN; Collin F; Delaney TF; Duffaud F; Filleron T; Fiore M; Gelderblom H; George S; Grimer R; Grosclaude P; Gronchi A; Haas R; Hohenberger P; Issels R; Italiano A; Jooste V; Krarup-Hansen A; Le Péchoux C; Mussi C; Oberlin O; Patel S; Piperno-Neumann S; Raut C; Ray-Coquard I; Rutkowski P; Schuetze S; Sleijfer S; Stoeckle E; Van Glabbeke M; Woll P; Gourgou-Bourgade S; Mathoulin-Pélissier S
Ann Oncol; 2015 May; 26(5):865-872. PubMed ID: 25070543
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 May; 26(5):873-879. PubMed ID: 25725046
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F; Bonsing B; Conroy T; Dousseau A; Glimelius B; Haustermans K; Lacaine F; Van Laethem JL; Aparicio T; Aust D; Bassi C; Berger V; Chamorey E; Chibaudel B; Dahan L; De Gramont A; Delpero JR; Dervenis C; Ducreux M; Gal J; Gerber E; Ghaneh P; Hammel P; Hendlisz A; Jooste V; Labianca R; Latouche A; Lutz M; Macarulla T; Malka D; Mauer M; Mitry E; Neoptolemos J; Pessaux P; Sauvanet A; Tabernero J; Taieb J; van Tienhoven G; Gourgou-Bourgade S; Bellera C; Mathoulin-Pélissier S; Collette L
Eur J Cancer; 2014 Nov; 50(17):2983-93. PubMed ID: 25256896
[TBL] [Abstract][Full Text] [Related]
7. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
Leon MB; Piazza N; Nikolsky E; Blackstone EH; Cutlip DE; Kappetein AP; Krucoff MW; Mack M; Mehran R; Miller C; Morel MA; Petersen J; Popma JJ; Takkenberg JJ; Vahanian A; van Es GA; Vranckx P; Webb JG; Windecker S; Serruys PW
J Am Coll Cardiol; 2011 Jan; 57(3):253-69. PubMed ID: 21216553
[TBL] [Abstract][Full Text] [Related]
8. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
9. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar A; Negrier S; Sylvester R; Joniau S; Mulders P; Powles T; Bex A; Bonnetain F; Bossi A; Bracarda S; Bukowski R; Catto J; Choueiri TK; Crabb S; Eisen T; El Demery M; Fitzpatrick J; Flamand V; Goebell PJ; Gravis G; Houédé N; Jacqmin D; Kaplan R; Malavaud B; Massard C; Melichar B; Mourey L; Nathan P; Pasquier D; Porta C; Pouessel D; Quinn D; Ravaud A; Rolland F; Schmidinger M; Tombal B; Tosi D; Vauleon E; Volpe A; Wolter P; Escudier B; Filleron T;
Ann Oncol; 2015 Dec; 26(12):2392-8. PubMed ID: 26371288
[TBL] [Abstract][Full Text] [Related]
10. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
11. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
12. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A).
Nakamura K; Shibata T; Takashima A; Yamamoto S; Fukuda H
Jpn J Clin Oncol; 2012 Oct; 42(10):896-902. PubMed ID: 22844128
[TBL] [Abstract][Full Text] [Related]
14. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
15. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Punt CJ; Buyse M; Köhne CH; Hohenberger P; Labianca R; Schmoll HJ; Påhlman L; Sobrero A; Douillard JY
J Natl Cancer Inst; 2007 Jul; 99(13):998-1003. PubMed ID: 17596575
[TBL] [Abstract][Full Text] [Related]
16. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
17. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
Pfirrmann M; Hochhaus A; Lauseker M; Saussele S; Hehlmann R; Hasford J
Leukemia; 2011 Sep; 25(9):1433-8. PubMed ID: 21597465
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
19. Statistical considerations for the next generation of clinical trials.
Wu W; Shi Q; Sargent DJ
Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
[TBL] [Abstract][Full Text] [Related]
20. Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
Case D; Morgan T
Clin Trials; 2008; 5(3):222-3; discussion 223-4. PubMed ID: 18559410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
